TP53 and non-small cell lung carcinoma: Thus, it is essential to validate, at the cellular level, and in the context of a specific TP53 mutation site, the “two sides” of the tumor biological effects of FOSB observed in the NSCLC population with different genetic backgrounds of TP53. It has been reported that codons 175, 248, and 273 within the DNA binding domain (DBD) of the TP53 gene are the “hotspot” mutation sites where missense mutations occur most frequently in human tumors including NSCLC [20, 27].